New developments in acute anticoagulation therapy

Preview

Heparin has been in use for more than 40 years and is still an important agent for inhibiting plasma- and surface-bound thrombin. However, modifications have produced low-molecular-weight heparin, which has better bioavailability and perhaps other advantages over traditional heparin. Another direction of research in anticoagulation therapy has been toward new antithrombin- independent agents. Dr Carter describes the present status of studies on heparin and its derivatives, direct thrombin inhibitors, and ancrod, a component of snake venom.

Additional information

Notes on contributors

Cedric J. Carter

Cedric J. Carter, MB(Lond), FRCPC Dr Carter is associate professor of pathology and laboratory medicine, University of British Columbia, Vancouver.